Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for lymphoma.

The investigators hypothesize that after stem cell mobilization with G-CSF plus IV AMD3100, a significantly higher proportion of lymphoma patients will collect ≥ 2 x 10E6 CD34+ cells/kg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

NCT00914849

Hematologic Neoplasms

COMPLETED PHASE2

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

NCT00241358

Leukemia, Myeloid, Acute Leukemia, Myelogenous, Chronic Leukemia, Lymphoblastic, Acute +5 more

COMPLETED PHASE1/PHASE2

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

NCT01026987

Stem Cell Transplant Patients

COMPLETED PHASE1

Long-Term Follow Up Study for AMD3100 Patients

NCT00476294

Myeloma

COMPLETED

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642

Non-Hodgkin Lymphoma Hodgkin Lymphoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autologous stem cell transplantation (ASCT) is indicated for patients with non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who have primary progressive disease or who relapse after a chemotherapy-induced complete remission. For these patients, as for other patients undergoing autologous transplantation, the number of CD34+ cells collected is a reliable predictor of neutrophil and platelet (PLT) engraftment after transplantation.

AMD3100 (plerixafor) is a promising new mobilizing agent that has demonstrated efficacy in patients with NHL, HL, and multiple myeloma (MM). Although efficacious, the subcutaneous dosing of AMD3100 requires that patients receive the drug in the evening prior to apheresis, which can present logistical problems. Intravenous dosing of AMD3100 may result in a faster rise in peripheral CD34+ cell count, so that the drug can be administered the same day as apheresis. Intravenous dosing may also increase the peak CD34+ cell count, improving the number of CD34+ cells collected via apheresis.

This Phase I/II study will evaluate the safety and efficacy of intravenous AMD3100 added to the standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for Hodgkin and non-Hodgkin lymphomas.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, Non-Hodgkin Hodgkin Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

240 µg/kg SC AMD3100 Day -5

10 µg/kg SC G-CSF Day -4 thru Day -1

160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1

Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)

Group Type EXPERIMENTAL

AMD3100

Intervention Type DRUG

G-CSF

Intervention Type DRUG

Apheresis

Intervention Type PROCEDURE

Cohort 2

240 µg/kg SC AMD3100 Day -5

10 µg/kg SC G-CSF Day -4 thru Day -1

240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1

Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)

Group Type EXPERIMENTAL

AMD3100

Intervention Type DRUG

G-CSF

Intervention Type DRUG

Apheresis

Intervention Type PROCEDURE

Cohort 3

240 µg/kg SC AMD3100 Day -5

10 µg/kg SC G-CSF Day -4 thru Day -1

320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1

Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)

Group Type EXPERIMENTAL

AMD3100

Intervention Type DRUG

G-CSF

Intervention Type DRUG

Apheresis

Intervention Type PROCEDURE

Cohort 4

240 µg/kg SC AMD3100 Day -5

10 µg/kg SC G-CSF Day -4 thru Day -1

400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1

Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)

Group Type EXPERIMENTAL

AMD3100

Intervention Type DRUG

G-CSF

Intervention Type DRUG

Apheresis

Intervention Type PROCEDURE

Phase II

240 µg/kg SC AMD3100 Day -5

10 µg/kg SC G-CSF Day -4 thru Day -1

MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1

Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)

Group Type EXPERIMENTAL

AMD3100

Intervention Type DRUG

G-CSF

Intervention Type DRUG

Apheresis

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMD3100

Intervention Type DRUG

G-CSF

Intervention Type DRUG

Apheresis

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plerixafor Neupogen Filgrastim Leukopheresis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 75 years
* Diagnosis of HL or NHL eligible for autologous transplantation
* 30 days since last cycle of chemotherapy
* ECOG performance status of 0 or 1
* The patient has recovered from all acute toxic effects of prior chemotherapy
* WBC \>3.0 X 109/l
* Absolute PMN count \>1.5 X 109/l
* PLT count \>100 X 109/l
* Serum creatinine ≤ 2.2 mg/dl
* AST (SGOT), ALT (SGPT) and total bilirubin \< 2X upper limit of normal (ULN)
* Left ventricle ejection fraction \> 45% (by ECHO or MUGA scan)
* FEV1 \> 60% of predicted or DLCO \> 45% of predicted
* Negative for HIV on standard transplant workup
* Signed informed consent
* Are surgically or biologically sterile or willing to practice acceptable birth control, as follows:

* Females of child bearing potential must agree to abstain from sexual activity or to use a medically approved contraceptive measure/regimen during and for 3 months after the treatment period. Women of child bearing potential must have a negative serum or urine pregnancy test at the time of enrollment. Acceptable methods of birth control include oral contraceptive, intrauterine device (IUD), transdermal/implanted or injected contraceptives and abstinence.
* Males must agree to abstain from sexual activity or agree to utilize a medically approved contraception method during and for 3 months after the treatment period

Exclusion Criteria

* A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications
* Patients who have failed previous collections
* A residual acute medical condition resulting from prior chemotherapy
* Acute infection
* Fever (temp \>38C/100.4F) on the day of start of treatment
* Positive pregnancy test in female patients
* Lactating females
* Patients of child bearing potential unwilling to implement adequate birth control
* Patients whose actual body weight exceeds 150% of their ideal body weight
* History of ventricular arrhythmias
* Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization phase
* Patients who have deterioration of their clinical status or laboratory parameters between the time of enrollment and transplantation such that they no longer meet entry criteria may be removed from study at the discretion of the treating physician, principal investigator, or sponsor

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No